Sanctuary Advisors LLC Buys 13,529 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sanctuary Advisors LLC lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 46.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 42,903 shares of the pharmaceutical company's stock after purchasing an additional 13,529 shares during the period. Sanctuary Advisors LLC's holdings in Vertex Pharmaceuticals were worth $19,348,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Whalen Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the 3rd quarter valued at $662,000. Creative Planning raised its position in shares of Vertex Pharmaceuticals by 5.3% during the second quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company's stock valued at $37,084,000 after buying an additional 3,998 shares during the last quarter. Mizuho Securities USA LLC lifted its stake in shares of Vertex Pharmaceuticals by 289.0% in the third quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company's stock valued at $35,994,000 after buying an additional 57,497 shares during the period. Blue Trust Inc. grew its position in Vertex Pharmaceuticals by 640.0% during the second quarter. Blue Trust Inc. now owns 1,443 shares of the pharmaceutical company's stock worth $676,000 after buying an additional 1,248 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in Vertex Pharmaceuticals during the second quarter valued at about $21,008,000. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ VRTX traded up $0.92 during midday trading on Friday, hitting $465.04. The stock had a trading volume of 404,195 shares, compared to its average volume of 1,182,762. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $391.01 and a fifty-two week high of $519.88. The firm has a market cap of $119.76 billion, a P/E ratio of -233.23 and a beta of 0.36. The company's 50-day simple moving average is $473.33 and its 200 day simple moving average is $475.80.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. The firm had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The company's quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the business posted $3.67 EPS. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Canaccord Genuity Group lifted their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a "sell" rating in a report on Wednesday, November 6th. StockNews.com lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Thursday, November 21st. Scotiabank raised their price objective on shares of Vertex Pharmaceuticals from $480.00 to $486.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 5th. Oppenheimer decreased their target price on shares of Vertex Pharmaceuticals from $550.00 to $540.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. Finally, Bank of America dropped their price target on shares of Vertex Pharmaceuticals from $550.00 to $541.00 and set a "buy" rating for the company in a research report on Monday, October 14th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $506.20.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.